1. Home
  2. REFI vs CCCC Comparison

REFI vs CCCC Comparison

Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Atlantic Real Estate Finance Inc.

REFI

Chicago Atlantic Real Estate Finance Inc.

N/A

Current Price

$10.77

Market Cap

278.8M

Sector

Real Estate

ML Signal

N/A

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

404.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REFI
CCCC
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
278.8M
404.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
REFI
CCCC
Price
$10.77
$3.45
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
143.7K
2.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
15.79%
N/A
EPS Growth
N/A
16.45
EPS
0.57
N/A
Revenue
$48,857,628.00
$35,947,000.00
Revenue This Year
$17.47
N/A
Revenue Next Year
$0.06
N/A
P/E Ratio
$18.88
N/A
Revenue Growth
N/A
1.02
52 Week Low
$9.69
$1.69
52 Week High
$13.72
$5.17

Technical Indicators

Market Signals
Indicator
REFI
CCCC
Relative Strength Index (RSI) 52.52 35.36
Support Level $10.63 $3.40
Resistance Level $10.93 $3.91
Average True Range (ATR) 0.18 0.20
MACD 0.00 -0.07
Stochastic Oscillator 25.84 9.09

Price Performance

Historical Comparison
REFI
CCCC

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: